Alvotech (NASDAQ:ALVO) Sees Strong Trading Volume - What's Next?

Key Points

• Alvotech shares saw unusually heavy trading, with about 1.26 million shares changing hands—96% above the prior session—and the stock rising to $4.48 from $4.27.
• Analyst sentiment remains mixed: Evercore initiated coverage with an “outperform” rating, while other firms issued downgrades. The consensus rating is “Hold”, with an average price target of $7.60.
• Several major hedge funds increased their Alvotech positions, including Vanguard, Millennium Management, Goldman Sachs and Geode Capital. The biopharmaceutical company develops and manufactures biosimilars targeting major biologic therapies in areas such as immunology and oncology.

Shares of Alvotech (NASDAQ:ALVO - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 1,260,668 shares were traded during mid-day trading, an increase of 96% from the previous session's volume of 641,961 shares.The stock last traded at $4.48 and had previously closed at $4.27.

Analysts Set New Price Targets

ALVO has been the topic of several recent analyst reports. Evercore started coverage on shares of Alvotech in a research report on Friday, August 14th. They set an "outperform" rating on the stock. Wall Street Zen cut Alvotech from a "hold" rating to a "sell" rating in a research note on Saturday, May 23rd. Finally, Weiss Ratings downgraded shares of Alvotech from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 9th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, Alvotech currently has a consensus rating of "Hold" and an average price target of $7.60.

Alvotech Stock Performance

The business's 50 day moving average is $3.66 and its two-hundred day moving average is $3.74. The firm has a market capitalization of $1.35 billion, a PE ratio of -7.34 and a beta of 0.18.

Hedge Funds Weigh In On Alvotech

Several hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Alvotech by 2.7% during the 3rd quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company's stock valued at $35,481,000 after purchasing an additional 114,255 shares during the period. Millennium Management LLC boosted its stake in Alvotech by 1,707.7% in the 4th quarter. Millennium Management LLC now owns 357,176 shares of the company's stock worth $1,832,000 after purchasing an additional 337,417 shares during the period. Goldman Sachs Group Inc. grew its holdings in Alvotech by 88.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company's stock valued at $1,331,000 after buying an additional 122,089 shares in the last quarter. Geode Capital Management LLC grew its holdings in Alvotech by 10.7% during the 4th quarter. Geode Capital Management LLC now owns 254,921 shares of the company's stock valued at $1,308,000 after buying an additional 24,667 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC bought a new stake in shares of Alvotech during the second quarter valued at about $1,782,000.

Alvotech Company Profile

Alvotech NASDAQ: ALVO is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source